Having recently reached a DKK 1bn (USD 153m) milestone, life science incubator Bioinnovation Institute's (BII) ambitions reach new heights.
Since its founding in 2018, when the Novo Nordisk Foundation gave BII an initial grant of DKK 392m (USD 60m), a total of 79 start-ups have gone through or are currently in one of BII's programs.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.